|
Noxxon Pharma AG is a small-to-medium-sized company founded in year 1997 in Berlin, Germany and since then is headquartered there. The stocks of the company are not publicly traded. The term ''Noxxon'' is a registered trademark〔(DPMAregister )〕 and represents a palindrome which reads the same in either forward or reverse direction. The subject of the company's business is development of drugs. The active ingredients are discovered under a patented technology yielding L-RNA molecules, which are of mirror-image configuration compared to natural occurring D-RNA molecules. This class of agents is termed Spiegelmer, which is a registered trademark of Noxxon Pharma AG.〔(DPMAregister )〕 The word 'Spiegel' is the German word for 'mirror'. The company is member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). == Products == While no Spiegelmer is on the market yet, some candidates are already in clinical trials necessary for approval. Drug candidates for different diseases (indications) are evaluated: In the area of oncology (cancer) a Spiegelmer is under development for treatment of Multiple myeloma (MM) and Chronic lymphocytic leukemia (CLL). A different Spiegelmer is currently being tested for the treatment of a progressive kidney disease in diabetics, Diabetic nephropathy. Favorable results were reported in June, 2014 in a company press release.〔http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf.〕 A third Spiegelmer is currently in a clinical trial for the treatment of Anemia of chronic disease. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Noxxon Pharma」の詳細全文を読む スポンサード リンク
|